We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
Cap. Flow
-$43.5M
Cap. Flow %
-1.41%
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$41.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$21.9M
3
UTHR icon
United Therapeutics
UTHR
+$14.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$12.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.5M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$21.8M
2
STE icon
Steris
STE
+$20M
3
ILMN icon
Illumina
ILMN
+$18.6M
4
WAT icon
Waters Corp
WAT
+$17.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.67%
2 Real Estate 2.94%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
126
Sanofi
SNY
$103B
$4.29M 0.14%
81,554
– –
PRAH
127
DELISTED
PRA Health Sciences, Inc.
PRAH
$4.14M 0.13%
25,068
-78,875
-76% -$13.2M
ARDX icon
128
Ardelyx
ARDX
$1.22B
$4.09M 0.13%
539,408
-68,290
-11% -$505K
NVO
129
Novo Nordisk
NVO
$208B
$4.05M 0.13%
96,812
– –
TCRR
130
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.87M 0.13%
235,808
– –
VIR icon
131
Vir Biotechnology
VIR
$1.46B
$3.85M 0.13%
81,400
– –
FMTX
132
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$3.73M 0.12%
149,825
– –
ARQT icon
133
Arcutis Biotherapeutics
ARQT
$3.36B
$3.59M 0.12%
131,633
– –
TAK icon
134
Takeda Pharmaceutical
TAK
$54.6B
$3.54M 0.11%
210,146
– –
TECH icon
135
Bio-Techne
TECH
$11.2B
$3.42M 0.11%
30,400
– –
MEDP icon
136
Medpace
MEDP
$16.1B
$3.33M 0.11%
18,871
– –
MREO
137
Mereo BioPharma
MREO
$54.7M
$3.31M 0.11%
1,044,790
+47,500
+5% +$159K
XENE icon
138
Xenon Pharmaceuticals
XENE
$6.06B
$3.15M 0.1%
169,030
+3,132
+2% +$57.7K
SRRK icon
139
Scholar Rock
SRRK
$5.67B
$3.15M 0.1%
108,833
+60,964
+127% +$1.87M
HR
140
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.14M 0.1%
104,024
– –
TVTX icon
141
Travere Therapeutics
TVTX
$5.2B
$3.11M 0.1%
212,869
– –
NKTR icon
142
Nektar Therapeutics
NKTR
$2.39B
$3.1M 0.1%
12,029
– –
BCEL
143
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3M 0.1%
352,424
– –
PHG icon
144
Philips
PHG
$25.7B
$2.83M 0.09%
68,917
-1,278
-2% -$59.1K
INSM icon
145
Insmed
INSM
$21.4B
$2.8M 0.09%
98,387
– –
JNCE
146
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.6M 0.08%
382,237
– –
MLTX icon
147
MoonLake Immunotherapeutics
MLTX
$1.57B
$2.58M 0.08%
250,000
– –
XRN
148
Chiron Real Estate Inc
XRN
$514M
$2.58M 0.08%
34,979
– –
DRNA
149
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.54M 0.08%
68,150
– –
ENDP
150
DELISTED
Endo International plc
ENDP
$2.49M 0.08%
531,570
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
  • Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
  • Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
  • Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
  • Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
  • Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.